Washington Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Washington Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-2,282	Closed	-$422K	–	138
2014 Q4	$422K	Hold	2,282	–	–	0.18%	109
2014 Q3	$378K	Hold	2,282	–	–	0.15%	113
2014 Q2	$357K	Hold	2,282	–	–	0.13%	128
2014 Q1	$347K	Sell	2,282 -15,168	-87%	-$2.41M	0.13%	128
2013 Q4	$2.32M	Buy	17,450 +938	+6%	+$113K	0.56%	74
2013 Q3	$1.92M	Sell	16,512 -956	-5%	-$105K	0.51%	85
2013 Q2	$1.61M	Buy	+17,468	New	+$1.68M	0.42%	113

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Washington Capital Management's ALXN Position: Q1 2015 in Review

Washington Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2015, closing a stake of 2,282 shares — an estimated $422K sold.

Washington Capital Management first reported a position in ALXN in Q2 2013 and held it in 7 quarters. The position peaked at $2.32M in Q4 2013. 566 funds tracked by Wall St. Rank hold ALXN as of Q1 2015.

Washington Capital Management reported no remaining Alexion Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
Washington Capital Management sold 2,282 Alexion Pharmaceuticals shares in Q1 2015, an estimated $422K.
Washington Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 7 quarters.
Washington Capital Management's Alexion Pharmaceuticals position peaked at $2.32M in Q4 2013.
566 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2015.

Based on Washington Capital Management's 13F filing for Q1 2015, filed 7 May 2015.